REG - ReNeuron Group plc - Total Voting Rights

ReNeuronAnnouncement

02/05/2019 15:45

RNS Number : 9384X
ReNeuron Group plc
02 May 2019
 


 
 



2 May 2019


AIM: RENE



 
ReNeuron Group plc
 
Total Voting Rights
 
At 30 April 2019, the Company has 31,712,921 ordinary shares in issue, all with voting rights. The Company holds no ordinary shares in treasury. The above figure of 31,712,921 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.
  
 
ENDS
ENQUIRIES:
 



ReNeuron


+44 (0)20 3819 8400




Olav Hellebø, Chief Executive Officer








Michael Hunt, Chief Financial Officer
 








Buchanan


+44 (0) 20 7466 5000




Mark Court, Sophie Wills, Tilly Abraham
 


















Stifel Nicolaus Europe Limited


+44 (0) 20 7710 7600




Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
 








N+1 Singer


+44 (0) 20 7496 3000




Aubrey Powell, Mark Taylor (Joint Broker)







 
 
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRUGUPCAUPBGCP